GlassScriptPhysician profile
James A Taki
NPI 1114002458
$2,971.97
in general payments reported to CMS, 2019-2025
32 companies · $616 in 2025
The $616 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $628 · 2020: $154 · 2021: $127 · 2022: $98.89 · 2023: $827 · 2024: $522 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,964.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $565.60 | 2019-2025 | |
| Glaxosmithkline, LLC. | $286.08 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Amgen INC. | $249.35 | 2019-2020 | |
| Novo Nordisk INC | $248.42 | 2019-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $174.91 | 2019-2023 | Xarelto |
| Lundbeck LLC | $158.76 | 2023-2024 | Vyepti |
| Inspire Medical Systems, INC. | $147.17 | 2024 | Inspire |
| Abbott Laboratories | $144.54 | 2023-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.25 | 2019-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $124.72 | 2023 | Camzyos |
| Lilly USA, LLC | $95.12 | 2019-2025 | Zepbound, Mounjaro |
| Idorsia Pharmaceuticals US INC | $80.01 | 2023-2025 | Quviviq, Quviviq |
| Astellas Pharma US INC | $67.22 | 2019-2024 | Veozah |
| Ironwood Pharmaceuticals, INC | $55.75 | 2019 | |
| Dynavax Technologies Corporation | $41.08 | 2023-2024 | Heplisav-B |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $40.53 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $39.51 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.17 | 2019 | |
| Seqirus USA INC | $36.14 | 2023-2024 | Flucelvax, Fluad, Fluad Quadrivalent |
| Abbvie INC. | $31.95 | 2023-2024 | Linzess |
| Dexcom, INC. | $30.19 | 2023-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $29.97 | 2024-2025 | Airsupra, Breztri |
| Supernus Pharmaceuticals, INC. | $23.58 | 2025 | Qelbree |
| Merck Sharp & Dohme LLC | $18.82 | 2024 | Proquad, Gardasil, Gardasil 9 |
| Cipher Pharmaceuticals US LLC | $16.73 | 2025 | Spinosad, Natroba |
| Kaleo, INC. | $15.47 | 2022 | |
| Eisai INC. | $15.29 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.29 | 2022 | |
| Allergan, INC. | $14.73 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $14.00 | 2021 | |
| Aimmune Therapeutics, INC. | $13.52 | 2025 | Zenpep |
| Teva Pharmaceuticals USA, INC. | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Taki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.